David Colleran - 10 Mar 2025 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)

Role
EVP, General Counsel, Corp Sec
Signature
/s/ David Colleran
Issuer symbol
ANIK
Transactions as of
10 Mar 2025
Net transactions value
-$26,658
Form type
4
Filing time
11 Mar 2025, 17:17:58 UTC
Previous filing
19 Mar 2024
Next filing
13 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANIK Common Stock Options Exercise $0 +5,465 +16% $0.000000 39,590 10 Mar 2025 Direct F1, F2
transaction ANIK Common Stock Tax liability $26,658 -1,604 -4.1% $16.62 37,986 10 Mar 2025 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANIK Restricted Stock Unit Options Exercise $0 -5,465 -50% $0.000000 5,465 10 Mar 2025 Common Stock 5,465 $0.000000 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the second vesting installment of RSUs granted on March 9, 2023.
F2 Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 800 shares purchased on May 14, 2024 and 330 shares purchased on November 14, 2024.
F3 Reflects an aggregate of 1,604 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2025.
F4 Reflects the closing price of ANIK common stock on March 7, 2025, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations.
F5 Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024.